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the present study, high enkephalin levels were restricted 
to patients with ascites. Finally, most other peptides and 
amines found in increased circulating levels in patients 
with advanced cirrhosis (e.g. insulin, renin, catechol- 
amines) have an enhanced release rate-and not an 
impaired hepatic inactivation-as the main cause of the 
increased plasma levels (5, 6). However, in my opinion, 
an enhanced release of methionine enkephalin would be 
equally interesting. 
As admitted by the authors, there is experimental 
evidence of the co-release of methionine enkephalin and 
epinephrine from the adrenal glands during sympathetic 
activation, which is in accord with the positive correla- 
tion between plasma methionine enkephalin and epi- 
nephrine demonstrated in their study. Thus, the in- 
creased methionine enkephalin might simply follow the 
sympathoadrenal overactivity in the same way as neu- 
ropeptide Y follows the release of norepinephrine. 
Like most previous reports on endogenous vasodi- 
lators, Thornton and coworkers did not find any rela- 
tionship between the circulating level of the potential 
vasodilator and the decreased arterial blood pressure. 
This may be due to the fact that a t  least three powerful 
vasoconstrictor systems (renin-angiotensin-aldosterone, 
sympathoadrenal and vasopressin) may compensate for 
the fall in arterial blood pressure (1). 
The authors propose that increased plasma opioid 
peptide activity increases histamine release, which in 
turn leads to increased lymphatic permeability in the 
liver, lymph leakage and ascites formation. However, 
available evidence suggests that microvascular permea- 
bility is decreased in the cirrhotic liver, with defenestra- 
tion and appearance of a basement membrane (6). More 
likely, in my opinion, would be an effect of histamine on 
sinusoidal pressure (7). Moreover, these patients do not 
show signs of general edema due to lymphatic leakage, 
as one would expect if a blood-borne substance had 
increased the lymphatic permeability. 
Although some aspects of Thornton and coworkers’ 
interpretation may be questioned, the essential finding 
of a highly increased endogenous, vasodilator peptide is 
very important, and future longitudinal studies during 
development of hepatic ascites are anticipated with in- 
terest. 
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AUGMENTATION OF THE NATRIURETIC 
RESPONSE TO ATRIAL NATRIURETIC 
FACTOR IN CIRRHOSIS 
Ganger DR, Gottstein J,  Blei AT. Hemodynamic and 
renal effects of atrial natriuretic factor in portal hyper- 
tensive rats. Potentiation by Phe-Ile-Om-vasopressin. J 
Pharmacol Exp Ther 1988; 246941-945. 
ABSTRACT 
The effects of atrial natriuretic factor (ANF) on 
splanchnic hemodynamics and renal function in 
portal hypertensive models are described incom- 
pletely. Furthermore, ANF-induced vasodilata- 
tion and hypotension may limit the assessment of 
its own renal physiological effects. We infused 
ANF (human ANF 102-126) to anesthetized portal 
vein-ligated rats, a model with prehepatic portal 
hypertension. Arterial pressure was reduced by 
1796, but portal pressure was unaffected. Diuresis 
and natriuresis were explained in part by an in- 
crease in glomerular filtration rate; in addition, 
renal vascular resistance was significantly de- 
creased. The natriuretic response to ANF was 
slightly, but significantly, decreased in portal hy- 
pertensive rats as compared to controls (fractional 
excretion of sodium, 1.8 f 0.4 us. 2.9 f 0.3; P < 
.05). The addition of Phe-Ile-Orn-vasopressin, a 
V 1 receptor agonist, normalized arterial pressure 
but induced a significant decrease in the portal 
pressure (15 f 0.9 mm Hg base line us. 12.8 f 0.7 
combination group; P < .01). Furthermore, the 
combination of both drugs markedly potentiated 
the natriuretic effects (0.4 2 0.1 pEq/min of con- 
trol us. 10.0 f 2.3 ANF us. 32.2 f 3.3 combination 
group; P < .001). The natriuretic potentiation re- 
sulted from increments in glomerular filtration 
rate and renal blood flow. Normalization of arte- 
rial pressure may enhance the renal physiological 
effects of ANF, in this portal hypertensive model. 
COMMENTS 
Identification, characterization and synthesis of atrial 
natriuretic factor (ANF) has raised considerable interest 
regarding volume regulation in cirrhosis (1). The natri- 
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uresis observed subsequent to administration of ANF is 
due to several factors, e.g. increase in glomerular filtra- 
tion rate (GFR), inhibition of tubuloglomerular feedback, 
induction of medullary “washout” and direct inhibition 
of tubular sodium reabsorption, the relative effects of 
which are difficult to determine. In addition, ANF sup- 
presses plasma concentrations of renin and aldosterone 
by inhibiting the synthesis of aldosterone and by block- 
ing the release of renin and aldosterone (1). ANF is of 
considerable therapeutic interest in cirrhosis with its 
proximal and distal tubular sodium retention and acti- 
vation of the renin-aldosterone system due to decreased, 
centrally effective, intravascular volume. 
In patients with cirrhosis, particularly those with as- 
cites, response to stimulation of endogenous release of 
ANF (2) as well as to low-dose infusion of synthetic ANF 
seems to be blunted (3). The reduced response might be 
due to alterations in the status of renal ANF receptors 
and/or to systemic and renal hemodynamic abnormali- 
ties. Several investigations support the contention that 
the decrease in mean arterial pressure following ANF 
administration in cirrhosis mediates the blunted natri- 
uresis (4-6). Following a bolus administration of 1 pg per 
kg ANF, mean arterial pressure decreased by 18 f 3 
mmHg in cirrhotic patients compared to 9 k 2 mmHg in 
control subjects (4). Thus, cirrhotic subjects with an 
activated renin-angiotensin-aldosterone system seem 
particularly sensitive to the vasodilatory effects of ANF. 
Natriuretic response of ANF (50 pg bolus followed by 50 
ng per kg.min infusion) in cirrhosis with ascites was 
more pronounced in those patients with lower basal 
plasma renin activity and plasma aldosterone concentra- 
tions (5). In contrast, patients with an activated renin- 
aldosterone system show further increase of plasma renin 
activity after ANF, concomitant with a decrease of renal 
plasma flow and of GFR, and no increase of natriuresis. 
In another study, the increase of natriuresis was in- 
versely related to changes in plasma renin activity, blood 
pressure and heart rate induced by ANF (6). Therefore, 
in cirrhotic patients with ascites, low-dose infusions of 
ANF (50 or 60 ngper kg-min) of ANF may induce greater 
natriuresis than high-dose infusions (75 or 300 ng per 
kg- min) (6). Thus, renal response to ANF administration 
may be optimized by a dosage large enough to induce 
natriuresis but small enough to avoid systemic hemody- 
namic alterations that activate compensatory responses. 
Alternatively, ANF-induced hypotension might be pre- 
vented by coadministration of vasconstrictor substances. 
Vasopressin (VP) would seem a suitable candidate with 
considerable natriuretic potential in patients with ascites 
and impaired renal function (7). 
In the study of Ganger et al. under comment, the 
effects of ANF were investigated in rats with portal 
hypertension induced by portal vein constriction. Infu- 
sion of ANF in high dose (500 ng per kg - min) induced a 
similar decrease of mean arterial pressure to that seen 
in control rats and only a small decrease in natriuresis. 
Interpretation of these data is somewhat difficult since 
no baseline renal perfusion and function values for the 
control group were provided. The second part of this 
pared the effects of an infusion of ANF (500 ng per kg. 
min) and of VP (5 ng per kg-min) individually and 
together. Indeed, the ANF-induced decrease in mean 
arterial pressure was prevented by the co-infusion of VP. 
Renal blood flow and GFR, which were only slightly 
affected by either agent alone, were increased signifi- 
cantly by the combination. The most remarkable find- 
ings were the potentiation of natriuresis and of diuresis 
by the combined infusion. Thus, in this model of portal 
hypertension, coadministration of VP with ANF over- 
came hypotension, the limiting factor for ANF adminis- 
tration, and potentiated the natriuresis and diuresis. If 
further studies in animal models confirm these findings, 
clinical trials of ANF together with vasopressin should 
be 
1. 
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7. 
undertaken. 
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HEPATOLOGY EZsewhere CORRESPONDENCE 
ANIMAL MODELS FOR ALCOHOLIC LIVER 
DISEASE 
To the Editor: 
We agree with most of the comments made in Dr. 
Mezey’s review of the paper of Ainley et al. in HEPA- 
TOLOGY Elsewhere (Hepatology 1989; 9:904). However, 
we disagree when Dr. Mezev writes that the intragastric 
Y u 
paper provides fascinating data. The investigators com- tube feeding rat model of experimental liver disease does 
